NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History.

GRIFOLS S A/S's stock split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

5 brokers have issued 12 month price targets for GRIFOLS S A/S's shares. Their forecasts range from $22.50 to $22.50. On average, they anticipate GRIFOLS S A/S's share price to reach $22.50 in the next year. This suggests a possible upside of 5.1% from the stock's current price. View Analyst Price Targets for GRIFOLS S A/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S.

Headlines about GRFS stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for GRIFOLS S A/S.

GRIFOLS S A/S saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 1,600,000 shares, a decline of 37.3% from the January 30th total of 2,550,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.6% of the shares of the company are short sold. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include Zoetis (ZTS), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG) and Teva Pharmaceutical Industries (TEVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), Nektar Therapeutics (NKTR), Horizon Therapeutics (HZNP), La Jolla Pharmaceutical (LJPC), Neurocrine Biosciences (NBIX), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV) and Abbott Laboratories (ABT).

GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FIL Ltd (1.78%), Credit Suisse AG (1.76%), Pictet Asset Management Ltd. (1.50%), Capital Research Global Investors (0.63%), Black Creek Investment Management Inc. (0.60%) and UBS Asset Management Americas Inc. (0.44%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Point72 Asset Management L.P., First Trust Advisors LP, Envestnet Asset Management Inc., Renaissance Technologies LLC, UBS Group AG, CIBC Private Wealth Group LLC and Todd Asset Management LLC.

GRFS stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Amia Capital LLP, Axiom International Investors LLC DE, Janus Henderson Group PLC, UBS Asset Management Americas Inc., FIL Ltd, SG Americas Securities LLC and Marshall Wace LLP.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $21.41.

GRIFOLS S A/S has a market capitalization of $14.72 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

The official website for GRIFOLS S A/S is http://www.grifols.com/.

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]